Video: Steven’s Ibogaine and 5-MeO-DMT experience at Casa Santa Isabel Ibogaine Clinic

Psychedelic ibogaine addiction recovery opioid

Only 5 to 10 percent of those with an opioid addiction successfully quit via conventional methods. To put that into perspective, in a room with 100 folks, only 5 to 10 will eventually achieve sobriety. A stunning 90 to 95 will remain mired in their addiction.

There must be another route, thought Dimitri H. In a riveting Rolling Stone piece by Jonathan Reiss, we are introduced to Dimitri and his 20 plus years of heroin addiction. After experimenting with the typical treatments, Dimitri booked a trip to Greece to bid farewell to his ancestral homeland and take his own life. But a last-minute stop in the Netherlands and an experimental treatment with ibogaine literally changed everything.

Today Dimitri is helping to treat thousands of opioid addicts whom conventional treatments have failed. He is a self-proclaimed “wounded warrior,” and based on the Alcoholics Anonymous program Dimitri has created a new program that is having great success.

Read full article here:

Colorado psilocybin dmt ibogaine

Colorado now joins a handful of states in advancing mental health treatment with previously banned substances. Bill HB22-1116 would establish “a policy review panel to study plant-based medicines to support mental health.” As author Nick Wills details in, “Colorado bill would study these natural hallucinogens,” psilocybin, psilocyn, dimethyltrytamine, and igobaine would be the eligible plants should the bill become law. 

Colorado has a history with similar decriminalization. In 2019 mushrooms with psilocybin were decriminalized where much research has shown the positive affect psilocyn has on serotonin, a hormone that affects our digestion, sleep, and mood. Ibogaine has yielded exceptional results with those addicted to opioids. 

In terms of next steps, the legislation will be reviewed by the Public & Behavioral Health and Human Services Committee in February 2022.

Read full article here:

Missouri patients could use psychedelic treatments under new gop right to try bill

In “Missouri Patients Could Use Psychedelic Treatments Under New GOP ‘Right-To-Try’ Bill,” journalist Kyle Jaeger drops some counter-intuitive facts – multiple Republican lawmakers in the Show-Me State are advancing bills to grant legal access to psychedelics such as LSD, psilocybin, and ibogaine. By access, Jaeger explains this is for folks with serious illnesses. Yet, the fact these are Republican lawmakers (as opposed to the usual Democrat suspects) has certainly piqued much interest.

In line with a federal right-to-try law passed back in 2018, the Missouri bill would essentially align the state statute with the federal one. Existing law applies to patients with terminal illnesses. The new law would expand access to those with life-threatening and debilitating conditions. 

An unlikely movement is afoot in middle America with a traditionally conservative party in the driver’s seat. Who would have guessed it!

Read the full article here:

US government will test ibogaine as an addiction treatment

When one typically thinks of psychedelics, the word “trip” is top of mind. Ibogaine has proven effective at treating addiction to tobacco, alcohol, and drugs. Yet, for those naysayers that continue to doubt the treatment based on the fact a “trip” is part of the equation, Will Yakowicz delivers a fascinating story on professor David Olson and his pursuit of a “no-trip” treatment.

In addition to being a faculty member at the University of California at Davis, Olson is also the co-founder of Delix, a company attempting to remove the “trip” from psychedelics while still preserving their therapeutic components. The company’s Delix-7 is said to do just that with ibogaine.

Olson is partial to a theory that the psychedelic trip is not necessary to treat the common addictions that ibogaine treats. The most important part, according to Olson, is the development of neuroplasticity which helps the brain form new neural connections in a positive way.

More research is needed, but this is indeed a promising line of research.

Read the full article here:

Revolutionizing Addiction Treatment: The Role of Ibogaine and Casa Santa Isabel’s Pioneering Efforts

In a groundbreaking shift within the realm of addiction treatment, ibogaine, a naturally occurring psychoactive substance found in the African iboga plant, is making headlines for its potential to significantly disrupt traditional approaches to opioid addiction recovery. A recent article in the New York Times highlights the growing interest in ibogaine’s unique ability to alleviate withdrawal symptoms and reduce cravings, offering hope to those trapped in the cycle of addiction.

Amidst the burgeoning field of psychedelic-assisted therapies, Casa Santa Isabel, located in the picturesque Baja California, Mexico, emerges as a beacon of hope and innovation. As one of the most respected and legitimate clinics for ibogaine therapy in Mexico, Casa Santa Isabel has dedicated itself to harnessing the transformative power of ibogaine under the guidance of licensed medical professionals.

The clinic’s approach is deeply rooted in scientific research and holistic care, ensuring that each treatment is tailored to the individual’s needs, providing not just a temporary reprieve but a profound, life-altering experience. With a focus on safety, compassion, and efficacy, Casa Santa Isabel stands at the forefront of ibogaine therapy, contributing to the growing body of evidence supporting its effectiveness in addiction treatment.

Ibogaine therapy at Casa Santa Isabel is not merely about substance cessation; it’s a comprehensive journey towards healing and self-discovery. Patients are supported through a meticulously structured program that addresses the psychological, physical, and spiritual facets of addiction, fostering an environment where profound transformation can occur.

As the world begins to recognize the potential of psychedelic-assisted therapies, Casa Santa Isabel’s work with ibogaine offers a compelling case study in the power of alternative treatments. The clinic’s commitment to research, patient care, and therapeutic innovation has solidified its status as a leading figure in the global movement towards more effective and compassionate addiction treatment solutions.

For those seeking a path out of addiction, Casa Santa Isabel represents a fusion of cutting-edge therapy and heartfelt care, embodying the promise of a future where healing and hope are within reach for everyone affected by opioid addiction.

Psychedelics can change humanity for the better its time to unlock their power

MAPS (Multidisciplinary Association for Psychedelic Studies) is a non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics. Rick Doblin is a researcher at MAPS, and in “Psychedics can change humanity for the better. It’s time to unlock their power,” he delivers one of the most compelling cases for a range of psychedelics in helping those suffering from mental health and addiction issues. 

Doblin and his team work primarily with MDMA, ketamine, psilocybin, and ibogaine. As Doblin rightly states, indigenous communities worldwide have used psychedelics for hundreds, if not thousands of years in spiritual ceremonies and for healing. MAPS collaborates with researchers to facilitate the studies of psychedelic-assisted therapy with the hope that these interventions eventually become mainstream. MAPS research has found great effectiveness with ibogaine to treat opioid use disorder.   

Read full article here:

Ibogaine for addiction treatment

In 1962, a prominent scientist by the name of Howard Lotsof and his six friends decided to ingest ibogaine powder. The reason why? They were struggling mightily with heroin addiction and were on their last legs. The result – five of the six immediately quit heroin. 

Far from a robust longitudinal study, the results fascinated many. Fast-forward to the present and we know ibogaine has the potential to ameliorate a host of maladies. We’re treated to a comprehensive summary of the future of ibogaine in  “Ibogaine Use in Addiction Treatment: An Overview.” The global drug addiction treatment market is expected to reach a staggering $37.7 billion by 2027. It is hard to find anyone who does not know someone struggling with an addiction. It is for this reason that ibogaine is now on the radar of leading life-science firms.

Read full article here:

What if everyone took psychedelics

Psychedelics have a long history in popular culture. Typically viewed as counter-culture, primarily due to their Schedule-1 classification in the US and a Class-A classification in the UK, psychedelics are not entirely legal as any savvy reader could tell you. With that said, we have certainly witnessed waves of psychedelic renaissances over the years. Yet, it would appear that the last 5 years have been different. 

As Ed Prideaux details in “The worldview-changing drugs poised to go mainstream,” the difference we’re experiencing today is the psychiatric acceptance of psychedelics like ibogaine to treat a range of conditions: childhood autism, depression, criminal recidivism, schizophrenia, and alcoholism. A mind-boggling 6,000 studies covering 40,000 plus patients have been completed and the data could not be clearer.

Read full article here:

Osoyoos indian band eyes cutting edge drug treatment centre

Partnerships exist in all walks of life. But a collaborative project between the Osoyoos Indian Band (OIB) and a company called Universal Ibogaine might be the first of its kind. 

Ibogaine has been a staple of many West African communities. Derived from the iboga shrub, its history as a spiritual sacrament is well-founded. But it wasn’t until the 1960s that practitioners began to experiment with ibogaine’s psychedelic components to treat a wide range of mental health and addiction issues.

Universal Ibogaine trades on the TSX Venture Exchange and the objective of the OIB joint venture is to build out an ibogaine center detox clinic. In “Osoyoos Indian Band eyes cutting-edge drug treatment centre,” author Joe Fries details this novel partnership. The opioid crisis claimed a shocking 2,224 lives in B.C. in 2021. Both entities feel ibogaine can play a critical role in treating opioid addiction, serving as a viable alternative to the more standard opioid substitution therapies.

Read the full article here: